Table 5.
Stratified effect between gene promoter region methylation and MTNR1B genotypes for 5-year overall survival of colorectal cancer patients
| No. of subjects | No. of cases (%) |
Crude
|
Adjusteda
|
||||
|
HR
|
95%CI
|
HR
|
95%CI
|
||||
| rs1387153 (C>T) | |||||||
| TT vs CC + CT | CDKN2A | ||||||
| U | 10 | 4 (40.0) | 5.01 | (1.33 to 18.9) | 10.4 | (1.17 to 92.4) | |
| M | 11 | 4 (36.4) | 3.83 | (0.96 to 15.3) | 8.86 | (1.08 to 72.8) | |
| MGMT | |||||||
| U | 12 | 5 (41.7) | 3.63 | (1.05 to 12.6) | 8.57 | (1.67 to 44.1) | |
| M | 9 | 3 (33.3) | 4.93 | (1.10 to 22.1) | 3.05 | (0.33 to 28.0) | |
| rs2166706 (T>C) | |||||||
| CC vs TT + TC | CDKN2A | ||||||
| U | 10 | 4 (40.0) | 5.02 | (1.33 to 19.0) | 10.4 | (1.17 to 92.4) | |
| M | 13 | 5 (38.5) | 3.96 | (1.06 to 14.7) | 10.1 | (1.49 to 68.0) | |
| MGMT | |||||||
| U | 13 | 5 (38.5) | 3.07 | (0.89 to 10.7) | 6.28 | (1.54 to 25.7) | |
| M | 23 | 9 (39.1) | 6.25 | (1.56 to 25.1) | 8.28 | (0.95 to 72.3) | |
| rs10830963 (C>G) | |||||||
| GG vs CC + CG | CDKN2A | ||||||
| U | 13 | 5 (38.5) | 4.63 | (1.24 to 17.3) | 8.47 | (1.57 to 45.6) | |
| M | 10 | 5 (50.0) | 5.61 | (1.51 to 20.9) | 27.2 | (3.12 to 233) | |
| MGMT | |||||||
| U | 12 | 5 (41.7) | 3.47 | (1.00 to 12.0) | 8.50 | (1.98 to 36.5) | |
| M | 11 | 5 (45.5) | 7.91 | (1.89 to 33.2) | 9.80 | (1.42 to 67.5) | |
| rs1447352 (A>G) | |||||||
| AA vs GG + GA | CDKN2A | ||||||
| U | 22 | 6 (27.3) | 2.05 | (0.51 to 8.22) | 2.28 | (0.51 to 10.2) | |
| M | 28 | 8 (28.6) | 7.34 | (0.92 to 58.7) | 9.40 | (1.02 to 86.8) | |
| MGMT | |||||||
| U | 24 | 8 (33.3) | 3.94 | (0.84 to 18.6) | 19.4 | (2.94 to 128) | |
| M | 26 | 6 (23.1) | 2.77 | (0.56 to 13.7) | 2.04 | (0.35 to 12.0) | |
a
Adjusted for age, sex, stage, adjuvant chemotherapy, tumor location and the methylation status of CDKN2A and MLH1 or MGMT and MLH1 gene. U: Unmethylation; M: Methylation; HR: Hazard ratio.